Annual mammography screenings find cancer in patients at a less advanced stage than those who have a mammogram every two years, according to a new study presented at the annual meeting of the Radiological Society of North America.
The updated guidelines suggest clinicians screen adults ages 50-75 who are at average risk for the disease, and discuss the benefits, harms and costs of the three screening methods prior to undertaking any one procedure.
As of now the Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has enrolled 16,505 participants across a number of certified mammography clinics in the U.S., Canada and Argentina, with more sites and participants to come.
“Because BI-RADS 3 breast lesions have up to 2% likelihood of malignancy, it is imperative that optimal follow-up of BI-RADS 3 test results be addressed...," authors of the new study published in JACR wrote.
Manufacturers, hospitals, physicians and patient advocates have put significant marketing resources—including millions of dollars—into selling 3D mammograms to women, despite little evidence the modality is better than traditional mammography.